Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting
6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…Abstract Number: 582 • 2019 ACR/ARP Annual Meeting
Rheumacheck – Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Background/Purpose: In our region, the lack of knowledge, timely referral and access to laboratory tests and images are the main causes in the diagnostic delay…Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…Abstract Number: 938 • 2019 ACR/ARP Annual Meeting
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity
Background/Purpose: Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the…Abstract Number: 1507 • 2019 ACR/ARP Annual Meeting
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Patients (pts) with non-radiographic axial spondyloarthritis (nr-axSpA) report substantial impairment of productivity and daily activities due to the burden of their disease, similar to…Abstract Number: 1854 • 2019 ACR/ARP Annual Meeting
The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis
Background/Purpose: Bone marrow edema on MRI of the sacroiliac joints (SIJ) plays an important role in the ASAS (Assessment of Spondyloarthritis International Society) classification criteria…Abstract Number: 14 • 2019 ACR/ARP Annual Meeting
Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis, mainly affecting the axial skeleton. HLA-B27 confers the greatest genetic association in AxSpA. Exome sequencing in…Abstract Number: 590 • 2019 ACR/ARP Annual Meeting
What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?
Background/Purpose: Classification criteria for axSpA comprise an imaging and a clinical arm, the former requiring radiographic or MRI evidence of sacroiliitis. Several cohorts have reported…Abstract Number: 616 • 2019 ACR/ARP Annual Meeting
Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort
Background/Purpose: Psoriasis is a common feature of axial spondyloarthritis (axSpA) occuring in approximately 10% of patients with axSpA. It has been presumed that such an…Abstract Number: 1006 • 2019 ACR/ARP Annual Meeting
Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients
Background/Purpose: Vaspin is a novel adipokine with insulin-sensitizing functions that exerts anti-inflammatory actions1,2. It has been associated with cardiovascular (CV) disease, CV risk factors and…Abstract Number: 1509 • 2019 ACR/ARP Annual Meeting
Impact of Age and Disease Duration on the Response to IL-17A Inhibitor (Secukinumab) Treatment in Ankylosing Spondylitis: Pooled Results from the Phase 3 MEASURE Studies
Background/Purpose: Ankylosing spondylitis (AS), a chronic inflammatory disease involving the sacroiliac joints and spine, is associated with pain, stiffness, disability, and reduced quality of life.1,2…Abstract Number: 2212 • 2019 ACR/ARP Annual Meeting
Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
Background/Purpose: Axial Spondyloarthritis (axSpA) is characterized by abnormal bone formation that produces syndesmophytes, while paradoxically, inflammation causes increased bone resorption and skeletal fragility. Detection of…Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…Abstract Number: 1658 • 2018 ACR/ARHP Annual Meeting
Which Factors Influence the Diagnostic Delay in Patients with Axial Spondyloarthritis?
Background/Purpose: The interval from symptom onset till diagnosis in axial spondyloarthritis (axSpA) was reported a decade ago to be between five and ten years. The…Abstract Number: 661 • 2018 ACR/ARHP Annual Meeting
Bridging the Gap between Symptom Onset and Diagnosis in Axial Spondyloarthritis
Background/Purpose: Axial spondyloarthritis (axSpA) is diagnosed an average of 9 years after symptom onset (1), partly because inflammatory back pain (IBP) can be difficult…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 16
- Next Page »